BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zhang M, Merlin D. Nanoparticle-Based Oral Drug Delivery Systems Targeting the Colon for Treatment of Ulcerative Colitis. Inflamm Bowel Dis 2018;24:1401-15. [PMID: 29788186 DOI: 10.1093/ibd/izy123] [Cited by in Crossref: 40] [Cited by in F6Publishing: 35] [Article Influence: 13.3] [Reference Citation Analysis]
Number Citing Articles
1 Logozzi M, Di Raimo R, Mizzoni D, Fais S. Nanovesicles from Organic Agriculture-Derived Fruits and Vegetables: Characterization and Functional Antioxidant Content. Int J Mol Sci 2021;22:8170. [PMID: 34360936 DOI: 10.3390/ijms22158170] [Reference Citation Analysis]
2 Tan C, Fan H, Ding J, Han C, Guan Y, Zhu F, Wu H, Liu Y, Zhang W, Hou X, Tan S, Tang Q. ROS-responsive nanoparticles for oral delivery of luteolin and targeted therapy of ulcerative colitis by regulating pathological microenvironment. Materials Today Bio 2022;14:100246. [DOI: 10.1016/j.mtbio.2022.100246] [Reference Citation Analysis]
3 Placha D, Jampilek J. Chronic Inflammatory Diseases, Anti-Inflammatory Agents and Their Delivery Nanosystems. Pharmaceutics 2021;13:64. [PMID: 33419176 DOI: 10.3390/pharmaceutics13010064] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 7.0] [Reference Citation Analysis]
4 Hadji H, Bouchemal K. Advances in the treatment of inflammatory bowel disease: Focus on polysaccharide nanoparticulate drug delivery systems. Adv Drug Deliv Rev 2022;181:114101. [PMID: 34999122 DOI: 10.1016/j.addr.2021.114101] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Yang C, Merlin D. Nanoparticle-Mediated Drug Delivery Systems For The Treatment Of IBD: Current Perspectives. Int J Nanomedicine 2019;14:8875-89. [PMID: 32009785 DOI: 10.2147/IJN.S210315] [Cited by in Crossref: 24] [Cited by in F6Publishing: 9] [Article Influence: 8.0] [Reference Citation Analysis]
6 Cui Y, Zhu T, Zhang X, Chen J, Sun F, Li Y, Teng L. Oral delivery of superoxide dismutase by lipid polymer hybrid nanoparticles for the treatment of ulcerative colitis. Chinese Chemical Letters 2022. [DOI: 10.1016/j.cclet.2022.03.077] [Reference Citation Analysis]
7 Khare T, Palakurthi SS, Shah BM, Palakurthi S, Khare S. Natural Product-Based Nanomedicine in Treatment of Inflammatory Bowel Disease. Int J Mol Sci 2020;21:E3956. [PMID: 32486445 DOI: 10.3390/ijms21113956] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 6.5] [Reference Citation Analysis]
8 Liu C, Yan X, Zhang Y, Yang M, Ma Y, Zhang Y, Xu Q, Tu K, Zhang M. Oral administration of turmeric-derived exosome-like nanovesicles with anti-inflammatory and pro-resolving bioactions for murine colitis therapy. J Nanobiotechnology 2022;20:206. [PMID: 35488343 DOI: 10.1186/s12951-022-01421-w] [Reference Citation Analysis]
9 De Anda-flores Y, Carvajal-millan E, Campa-mada A, Lizardi-mendoza J, Rascon-chu A, Tanori-cordova J, Martínez-lópez AL. Polysaccharide-Based Nanoparticles for Colon-Targeted Drug Delivery Systems. Polysaccharides 2021;2:626-47. [DOI: 10.3390/polysaccharides2030038] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
10 Hmar EBL, Paul S, Boruah N, Sarkar P, Borah S, Sharma HK. Apprehending Ulcerative Colitis Management With Springing Up Therapeutic Approaches: Can Nanotechnology Play a Nascent Role? Curr Pathobiol Rep 2021;9:9-32. [DOI: 10.1007/s40139-020-00218-6] [Reference Citation Analysis]
11 Guo T, Song D, Cheng L, Zhang X. Interactions of tea catechins with intestinal microbiota and their implication for human health. Food Sci Biotechnol 2019;28:1617-25. [PMID: 31807334 DOI: 10.1007/s10068-019-00656-y] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 4.3] [Reference Citation Analysis]
12 Colgan SP. Resolvins resolve to heal mucosal wounds. Proc Natl Acad Sci U S A 2020;117:10621-2. [PMID: 32371481 DOI: 10.1073/pnas.2005652117] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
13 Cai X, Wang X, He M, Wang Y, Lan M, Zhao Y, Gao F. Colon-targeted delivery of tacrolimus using pH-responsive polymeric nanoparticles for murine colitis therapy. Int J Pharm 2021;606:120836. [PMID: 34217824 DOI: 10.1016/j.ijpharm.2021.120836] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
14 Wang D, Sun M, Zhang Y, Chen Z, Zang S, Li G, Li G, Clark AR, Huang J, Si L. Enhanced therapeutic efficacy of a novel colon-specific nanosystem loading emodin on DSS-induced experimental colitis. Phytomedicine 2020;78:153293. [PMID: 32777486 DOI: 10.1016/j.phymed.2020.153293] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
15 Zhang Y, Thanou M, Vllasaliu D. Exploiting disease-induced changes for targeted oral delivery of biologics and nanomedicines in inflammatory bowel disease. Eur J Pharm Biopharm 2020;155:128-38. [PMID: 32853696 DOI: 10.1016/j.ejpb.2020.08.017] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
16 Besednova NN, Zaporozhets TS, Kuznetsova TA, Makarenkova ID, Kryzhanovsky SP, Fedyanina LN, Ermakova SP. Extracts and Marine Algae Polysaccharides in Therapy and Prevention of Inflammatory Diseases of the Intestine. Mar Drugs 2020;18:E289. [PMID: 32486405 DOI: 10.3390/md18060289] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
17 Fatima N, Rehman S, Nabi B, Baboota S, Ali J. Harnessing nanotechnology for enhanced topical delivery of clindamycin phosphate. Journal of Drug Delivery Science and Technology 2019;54:101253. [DOI: 10.1016/j.jddst.2019.101253] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
18 Díez-Sainz E, Lorente-Cebrián S, Aranaz P, Riezu-Boj JI, Martínez JA, Milagro FI. Potential Mechanisms Linking Food-Derived MicroRNAs, Gut Microbiota and Intestinal Barrier Functions in the Context of Nutrition and Human Health. Front Nutr 2021;8:586564. [PMID: 33768107 DOI: 10.3389/fnut.2021.586564] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
19 Cuevas JM, Seoane-Rivero R, Navarro R, Marcos-Fernández Á. Coumarins into Polyurethanes for Smart and Functional Materials. Polymers (Basel) 2020;12:E630. [PMID: 32164198 DOI: 10.3390/polym12030630] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 4.5] [Reference Citation Analysis]
20 Shah BM, Palakurthi SS, Khare T, Khare S, Palakurthi S. Natural proteins and polysaccharides in the development of micro/nano delivery systems for the treatment of inflammatory bowel disease. Int J Biol Macromol 2020;165:722-37. [PMID: 33010274 DOI: 10.1016/j.ijbiomac.2020.09.214] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
21 Teruel AH, Gonzalez-Alvarez I, Bermejo M, Merino V, Marcos MD, Sancenon F, Gonzalez-Alvarez M, Martinez-Mañez R. New Insights of Oral Colonic Drug Delivery Systems for Inflammatory Bowel Disease Therapy. Int J Mol Sci 2020;21:E6502. [PMID: 32899548 DOI: 10.3390/ijms21186502] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 4.5] [Reference Citation Analysis]
22 Zu M, Ma Y, Cannup B, Xie D, Jung Y, Zhang J, Yang C, Gao F, Merlin D, Xiao B. Oral delivery of natural active small molecules by polymeric nanoparticles for the treatment of inflammatory bowel diseases. Adv Drug Deliv Rev 2021;176:113887. [PMID: 34314785 DOI: 10.1016/j.addr.2021.113887] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 19.0] [Reference Citation Analysis]
23 Minakshi P, Kumar R, Ghosh M, Brar B, Barnela M, Lakhani P. Application of Polymeric Nano-Materials in Management of Inflammatory Bowel Disease. Curr Top Med Chem 2020;20:982-1008. [PMID: 32196449 DOI: 10.2174/1568026620666200320113322] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
24 Hartwig O, Shetab Boushehri MA, Shalaby KS, Loretz B, Lamprecht A, Lehr CM. Drug delivery to the inflamed intestinal mucosa - targeting technologies and human cell culture models for better therapies of IBD. Adv Drug Deliv Rev 2021;175:113828. [PMID: 34157320 DOI: 10.1016/j.addr.2021.113828] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
25 Melchor-Martínez EM, Torres Castillo NE, Macias-Garbett R, Lucero-Saucedo SL, Parra-Saldívar R, Sosa-Hernández JE. Modern World Applications for Nano-Bio Materials: Tissue Engineering and COVID-19. Front Bioeng Biotechnol 2021;9:597958. [PMID: 34055754 DOI: 10.3389/fbioe.2021.597958] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
26 Leonard F, Srinivasan S, Liu X, Collnot E, Ferrari M, Lehr C, Godin B. Design and in vitro characterization of multistage silicon-PLGA budesonide particles for inflammatory bowel disease. European Journal of Pharmaceutics and Biopharmaceutics 2020;151:61-72. [DOI: 10.1016/j.ejpb.2020.03.020] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
27 Gong W, Yu J, Zheng T, Liu P, Zhao F, Liu J, Hong Z, Ren H, Gu G, Wang G, Wu X, Zhao Y, Ren J. CCL4-mediated targeting of spleen tyrosine kinase (Syk) inhibitor using nanoparticles alleviates inflammatory bowel disease. Clin Transl Med 2021;11:e339. [PMID: 33634985 DOI: 10.1002/ctm2.339] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
28 Naeem M, Awan UA, Subhan F, Cao J, Hlaing SP, Lee J, Im E, Jung Y, Yoo J. Advances in colon-targeted nano-drug delivery systems: challenges and solutions. Arch Pharm Res 2020;43:153-69. [DOI: 10.1007/s12272-020-01219-0] [Cited by in Crossref: 27] [Cited by in F6Publishing: 15] [Article Influence: 13.5] [Reference Citation Analysis]
29 Yang C, Zhang M, Sung J, Wang L, Jung Y, Merlin D. Autologous Exosome Transfer: A New Personalised Treatment Concept to Prevent Colitis in a Murine Model. J Crohns Colitis 2020;14:841-55. [PMID: 31710674 DOI: 10.1093/ecco-jcc/jjz184] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 10.0] [Reference Citation Analysis]
30 Wang Y, Wang J, Ma J, Zhou Y, Lu R. Focusing on Future Applications and Current Challenges of Plant Derived Extracellular Vesicles. Pharmaceuticals 2022;15:708. [DOI: 10.3390/ph15060708] [Reference Citation Analysis]
31 Turanlı Y, Acartürk F. Preparation and characterization of colon-targeted pH/Time-dependent nanoparticles using anionic and cationic polymethacrylate polymers. Eur J Pharm Sci 2022;171:106122. [PMID: 35007712 DOI: 10.1016/j.ejps.2022.106122] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
32 Naeem M, Lee J, Oshi MA, Cao J, Hlaing SP, Im E, Jung Y, Yoo JW. Colitis-targeted hybrid nanoparticles-in-microparticles system for the treatment of ulcerative colitis. Acta Biomater 2020;116:368-82. [PMID: 32937207 DOI: 10.1016/j.actbio.2020.09.017] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 7.5] [Reference Citation Analysis]
33 Barani M, Rahdar A, Sargazi S, Amiri MS, Sharma PK, Bhalla N. Nanotechnology for inflammatory bowel disease management: Detection, imaging and treatment. Sensing and Bio-Sensing Research 2021;32:100417. [DOI: 10.1016/j.sbsr.2021.100417] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 7.0] [Reference Citation Analysis]
34 Di Gioia S, Hossain MN, Conese M. Biological properties and therapeutic effects of plant-derived nanovesicles. Open Med (Wars) 2020;15:1096-122. [PMID: 33336066 DOI: 10.1515/med-2020-0160] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
35 Tang Q, Zhang W, Zhang C, Guan Y, Ding J, Yuan C, Tan C, Gao X, Tan S. Oxymatrine loaded nitric oxide-releasing liposomes for the treatment of ulcerative colitis. International Journal of Pharmaceutics 2020;586:119617. [DOI: 10.1016/j.ijpharm.2020.119617] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
36 Yang M, Zhang F, Yang C, Wang L, Sung J, Garg P, Zhang M, Merlin D. Oral Targeted Delivery by Nanoparticles Enhances Efficacy of an Hsp90 Inhibitor by Reducing Systemic Exposure in Murine Models of Colitis and Colitis-Associated Cancer. J Crohns Colitis 2020;14:130-41. [PMID: 31168612 DOI: 10.1093/ecco-jcc/jjz113] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
37 Zhang C, Chen Z, He Y, Xian J, Luo R, Zheng C, Zhang J. Oral colon-targeting core-shell microparticles loading curcumin for enhanced ulcerative colitis alleviating efficacy. Chin Med 2021;16:92. [PMID: 34551815 DOI: 10.1186/s13020-021-00449-8] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
38 Yu X, Wen T, Cao P, Shan L, Li L. Alginate-chitosan coated layered double hydroxide nanocomposites for enhanced oral vaccine delivery. Journal of Colloid and Interface Science 2019;556:258-65. [DOI: 10.1016/j.jcis.2019.08.027] [Cited by in Crossref: 25] [Cited by in F6Publishing: 16] [Article Influence: 8.3] [Reference Citation Analysis]
39 Oshi MA, Lee J, Naeem M, Hasan N, Kim J, Kim HJ, Lee EH, Jung Y, Yoo J. Curcumin Nanocrystal/pH-Responsive Polyelectrolyte Multilayer Core–Shell Nanoparticles for Inflammation-Targeted Alleviation of Ulcerative Colitis. Biomacromolecules 2020;21:3571-81. [DOI: 10.1021/acs.biomac.0c00589] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 5.5] [Reference Citation Analysis]
40 Wei W, Zhang Y, Li R, Cao Y, Yan X, Ma Y, Zhang Y, Yang M, Zhang M. Oral Delivery of Pterostilbene by L-Arginine-Mediated “Nano-Bomb” Carrier for the Treatment of Ulcerative Colitis. IJN 2022;Volume 17:603-16. [DOI: 10.2147/ijn.s347506] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
41 Auriemma G, Cerciello A, Aquino RP, Gaudio PD, Fusco BM, Russo P. Pectin and Zinc Alginate: The Right Inner/Outer Polymer Combination for Core-Shell Drug Delivery Systems. Pharmaceutics 2020;12:E87. [PMID: 31972993 DOI: 10.3390/pharmaceutics12020087] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 4.5] [Reference Citation Analysis]
42 Kulkarni N, Jain P, Shindikar A, Suryawanshi P, Thorat N. Advances in the colon-targeted chitosan based drug delivery systems for the treatment of inflammatory bowel disease. Carbohydrate Polymers 2022. [DOI: 10.1016/j.carbpol.2022.119351] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
43 Wang CJ, Byun MJ, Kim S, Park W, Park HH, Kim T, Lee JS, Park CG. Biomaterials as therapeutic drug carriers for inflammatory bowel disease treatment. Journal of Controlled Release 2022. [DOI: 10.1016/j.jconrel.2022.02.028] [Reference Citation Analysis]
44 Andretto V, Rosso A, Briançon S, Lollo G. Nanocomposite systems for precise oral delivery of drugs and biologics. Drug Deliv Transl Res 2021;11:445-70. [PMID: 33534107 DOI: 10.1007/s13346-021-00905-w] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
45 Zhang Y, Davis DA, AboulFotouh K, Wang J, Williams D, Bhambhani A, Zakrewsky M, Maniruzzaman M, Cui Z, Williams RO 3rd. Novel formulations and drug delivery systems to administer biological solids. Adv Drug Deliv Rev 2021;172:183-210. [PMID: 33705873 DOI: 10.1016/j.addr.2021.02.011] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 7.0] [Reference Citation Analysis]
46 Dos Santos AM, Carvalho SG, Meneguin AB, Sábio RM, Gremião MPD, Chorilli M. Oral delivery of micro/nanoparticulate systems based on natural polysaccharides for intestinal diseases therapy: Challenges, advances and future perspectives. J Control Release 2021;334:353-66. [PMID: 33901582 DOI: 10.1016/j.jconrel.2021.04.026] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
47 Goelen J, Alexander B, Wijesinghe HE, Evans E, Pawar G, Horniblow RD, Batchelor HK. Quantification of Fluid Volume and Distribution in the Paediatric Colon via Magnetic Resonance Imaging. Pharmaceutics 2021;13:1729. [PMID: 34684022 DOI: 10.3390/pharmaceutics13101729] [Reference Citation Analysis]
48 Singh A, Kaur K, Mandal UK, Narang RK. Nanoparticles as Budding Trends in Colon Drug Delivery for the Management of Ulcerative Colitis. CNANOM 2020;10:225-47. [DOI: 10.2174/2468187310999200621200615] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
49 Poláková L, Raus V, Cuchalová L, Poręba R, Hrubý M, Kučka J, Větvička D, Trhlíková O, Sedláková Z. SHARP hydrogel for the treatment of inflammatory bowel disease. Int J Pharm 2021;613:121392. [PMID: 34933083 DOI: 10.1016/j.ijpharm.2021.121392] [Reference Citation Analysis]
50 Bertoni S, Machness A, Tiboni M, Bártolo R, Santos HA. Reactive oxygen species responsive nanoplatforms as smart drug delivery systems for gastrointestinal tract targeting. Biopolymers 2020;111:e23336. [PMID: 31724750 DOI: 10.1002/bip.23336] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
51 Lemmens G, Van Camp A, Kourula S, Vanuytsel T, Augustijns P. Drug Disposition in the Lower Gastrointestinal Tract: Targeting and Monitoring. Pharmaceutics 2021;13:161. [PMID: 33530468 DOI: 10.3390/pharmaceutics13020161] [Reference Citation Analysis]